Company Overview - BGSF shares increased by 12.9% to $6.31 in the last trading session, with a notable trading volume, and have gained 25.6% over the past four weeks [1] - The company has agreed to sell its Professional Division to INSPYR Solutions for $99 million in cash, which includes IT consulting, finance & accounting, managed solutions, and near/offshore software services [1] Earnings Expectations - BGSF is expected to report break-even quarterly earnings per share (EPS), reflecting a year-over-year change of +100%, with revenues projected at $66.5 million, a decrease of 2.4% from the previous year [2] - The consensus EPS estimate for BGSF has been revised 100% higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [3] Industry Comparison - BGSF is part of the Zacks Business - Services industry, where another company, Crawford & Company B, saw its stock rise by 2.2% to $10.19, but has returned -0.9% over the past month [3] - Crawford & Company B's consensus EPS estimate remains unchanged at $0.24, representing a -4% change compared to the previous year, and holds a Zacks Rank of 3 (Hold) [4]

Company Overview - Flowserve (FLS) shares increased by 6.8% to close at $51.88, supported by strong trading volume, contrasting with a 3.8% decline over the past four weeks [1] - The company specializes in manufacturing pumps, valves, and other components for the oil and gas industries [3] Business Performance - The recent rally in Flowserve's stock is attributed to positive momentum in its aftermarket business, driven by robust demand across North America, Europe, the Middle East, and Latin America [2] - An increase in bookings in general industries, energy, and power end markets is bolstering the company's performance [2] Earnings Expectations - Flowserve is projected to report quarterly earnings of $0.77 per share, reflecting a year-over-year increase of 5.5% [3] - Expected revenues for the upcoming quarter are $1.21 billion, which represents a 4.7% increase compared to the same quarter last year [3] Market Sentiment - The consensus EPS estimate for Flowserve has remained stable over the last 30 days, indicating that stock price movements may not sustain without changes in earnings estimate revisions [5] - Flowserve currently holds a Zacks Rank of 3 (Hold), while IHI CORP, a competitor in the same industry, has a Zacks Rank of 1 (Strong Buy) [5][6]

Company Overview - Nurix Therapeutics, Inc. (NRIX) shares increased by 14.2% to close at $12.14, following a period of 5.7% loss over the past four weeks, indicating a significant rebound in stock performance [1][2] Licensing Agreement - Sanofi has exercised its option to exclusively license Nurix's STAT6 program, which includes the development candidate NX-3911, an oral and highly selective STAT6 degrader. Nurix is set to receive a license extension fee of $15 million and is eligible for up to $465 million in potential milestone payments, along with royalties on future sales [2] Financial Expectations - The company is expected to report a quarterly loss of $0.73 per share, reflecting a year-over-year change of -2.8%. Revenue is anticipated to be $17.31 million, representing a 43.2% increase from the same quarter last year [3] Earnings Estimate Revisions - The consensus EPS estimate for Nurix has been revised 1.1% higher over the last 30 days, suggesting a positive trend that may lead to price appreciation in the future [4] Industry Context - Nurix Therapeutics operates within the Zacks Medical - Biomedical and Genetics industry, where another company, Argenx SE (ARGX), saw a 2% increase in its stock price, closing at $584.61, despite a -11.8% return over the past month [4]

Group 1: Radware Overview - Radware (RDWR) shares increased by 5.5% to $22.24, following a strong market recovery amid easing US-China trade tensions [1] - The stock had previously experienced an 8.4% decline over the past four weeks [1] - The upcoming quarterly earnings are expected to be $0.23 per share, reflecting a year-over-year increase of 43.8%, with revenues projected at $70.5 million, up 8.3% from the previous year [2] Group 2: Earnings Estimates and Market Position - The consensus EPS estimate for Radware has remained unchanged over the last 30 days, indicating a lack of upward revisions which typically correlate with stock price movements [3] - Radware holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook [3] - The company is part of the Zacks Internet - Software industry, which includes other players like Fastly (FSLY) [3] Group 3: Fastly Overview - Fastly's consensus EPS estimate for the upcoming report is -$0.06, representing a year-over-year decline of 20% [4] - Fastly currently has a Zacks Rank of 4 (Sell), indicating a negative outlook [4]

Company Overview - MidCap Financial Investment (MFIC) shares increased by 11.8% to close at $11.70, following a notable trading volume compared to typical sessions, despite a 15.7% loss over the past four weeks [1] - The company benefits from a strong brand reputation, diversified product portfolio, and established customer relationships, which support premium pricing and customer loyalty [2] Financial Performance - MidCap Financial is expected to report quarterly earnings of $0.39 per share, reflecting an 11.4% decrease year-over-year, while revenues are projected to be $84.27 million, representing a 23.3% increase from the previous year [3] - The consensus EPS estimate for the quarter has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Context - MidCap Financial is part of the Zacks Financial - Miscellaneous Services industry, where Atlanticus Holdings Corporation (ATLC) also operates, having seen a 13.2% increase in its stock price recently [4] - Atlanticus has a consensus EPS estimate that has increased by 20% over the past month, indicating a positive outlook compared to the previous year [5]

Company Overview - LeMaitre Vascular (LMAT) shares increased by 7.7% to close at $83.90, following a relief rally in global markets due to a 90-day pause on tariff hikes by the United States [1] - The stock had previously experienced a 5.4% decline over the past four weeks [1] Earnings Expectations - LeMaitre is projected to report quarterly earnings of $0.50 per share, reflecting a year-over-year increase of 13.6% [2] - Expected revenues for the upcoming quarter are $57.8 million, which is an 8.1% increase compared to the same quarter last year [2] Stock Performance and Trends - The consensus EPS estimate for LeMaitre has remained unchanged over the last 30 days, indicating a lack of upward revisions in earnings estimates [3] - The stock currently holds a Zacks Rank of 2 (Buy), suggesting positive sentiment among analysts [3] Industry Context - LeMaitre operates within the Zacks Medical - Products industry, which includes other companies like AtriCure (ATRC) [3] - AtriCure's consensus EPS estimate has also remained unchanged at -$0.25, with a Zacks Rank of 3 (Hold) [4]

Company Overview - Addus HomeCare (ADUS) shares increased by 4.9% to close at $101, supported by higher trading volume compared to normal sessions [1] - The stock has gained 1.7% over the past four weeks [1] Financial Performance - Addus HomeCare is expected to report quarterly earnings of $1.33 per share, reflecting a year-over-year increase of 9.9% [2] - Projected revenues for the upcoming report are $339.94 million, which is a 21.1% increase from the same quarter last year [2] Market Trends - The recent stock price increase is linked to a relief rally in global markets due to a 90-day pause on tariff hikes announced by the United States [1] - The consensus EPS estimate for Addus HomeCare has remained unchanged over the last 30 days, indicating stability in earnings expectations [4] Industry Context - Addus HomeCare operates within the Zacks Medical - Outpatient and Home Healthcare industry, where another company, LifeStance Health Group (LFST), saw a 5.8% increase in its stock price [4] - LifeStance Health's consensus EPS estimate has decreased by 11.1% over the past month, but it still represents a 50% improvement from the previous year [5]

Company Overview - Elanco Animal Health Incorporated (ELAN) shares increased by 12.6% to close at $9.38, following a relief rally in global markets due to a 90-day pause on tariff hikes by the United States [1] - The stock had previously experienced a 17% loss over the past four weeks [1] Earnings Expectations - Elanco is expected to report quarterly earnings of $0.31 per share, reflecting a year-over-year decline of 8.8% [2] - Revenue projections stand at $1.17 billion, which is a decrease of 3.1% compared to the same quarter last year [2] Stock Performance Insights - The consensus EPS estimate for Elanco has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [3] - Elanco currently holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook [3] Industry Context - Elanco is part of the Zacks Medical - Outpatient and Home Healthcare industry, which includes other companies like Astrana Health, Inc. (ASTH) [3] - Astrana Health's consensus EPS estimate has decreased by 3.5% over the past month to $0.28, representing a year-over-year change of -9.7% [4] - Astrana Health also holds a Zacks Rank of 3 (Hold) [4]

Company Overview - Moody's shares ended the last trading session 10.6% higher at $438.59, following a significant volume of trading, contrasting with a 10.6% loss over the past four weeks [1] - The stock's rally was positively influenced by President Trump's announcement of a 90-day tariff suspension for non-retaliating countries, which alleviated trade tensions and boosted investor sentiment [2] Earnings Expectations - Moody's is expected to report quarterly earnings of $3.56 per share, reflecting a year-over-year increase of 5.6% [2] - Revenue expectations stand at $1.89 billion, which is a 5.9% increase from the same quarter last year [2] Earnings Estimate Revisions - The consensus EPS estimate for Moody's has been revised 0.8% higher over the last 30 days, indicating a positive trend that typically correlates with price appreciation [4] - Empirical research suggests that trends in earnings estimate revisions are strongly correlated with near-term stock price movements [3] Industry Comparison - Moody's holds a Zacks Rank of 2 (Buy) within the Zacks Financial - Miscellaneous Services industry [4] - Another company in the same industry, ChoiceOne Financial Services, Inc. (COFS), closed the last trading session 3.5% higher at $26.55, but has returned -11.8% over the past month [4]

Piper Sandler Companies (PIPR) shares ended the last trading session 14% higher at $240.34. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 15.9% loss over the past four weeks.Piper Sandler shares rallied sharply, benefiting from broad market strength following President Donald Trump’s announcement of a 90-day suspension on tariffs for non-retaliating countries. The policy shift eased trade tensions and improved ma ...